Trafermin clinical trials
How each study uses trafermin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Kaken Pharmaceutical (4) · Olympus Biotech Corporation (2)
Studies
Open first, then newest update. How each study uses trafermin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North StudyCompletedPhase 3Olympus Biotech CorporationNCT01217476Written as Trafermin 0.01% spray
- The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South StudyCompletedPhase 3Olympus Biotech CorporationNCT01217463Written as Trafermin 0.01% spray
- A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)CompletedPhase 3Kaken PharmaceuticalNCT01015404Written as Trafermin
- Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)CompletedPhase 3Kaken PharmaceuticalNCT00734708Written as Trafermin (genetical recombination)
- A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in JapanCompletedPhase 2Kaken PharmaceuticalNCT00199290Written as Trafermin (genetical recombination)
- Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2CompletedPhase 2Kaken PharmaceuticalNCT00514657Written as Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)
Codes
What other systems call trafermin · ClinicalTrials.gg INT004095
- MeSH (NLM) C114444traferminOne source NLM
- UNII (FDA) 333OX80X87TRAFERMINConfirmed FDA, NLM, Wikidata
- Wikidata Q30315131traferminConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152708TraferminOne source FDA
- DrugBank DB06244One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C114444 | trafermin | One source NLM |
| UNII (FDA) | 333OX80X87 | TRAFERMIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q30315131 | trafermin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152708 | Trafermin | One source FDA |
| DrugBank | DB06244 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.